You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Merck
Harvard Business School
Moodys
Medtronic
Colorcon

Last Updated: September 30, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,517,219

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,517,219 protect, and when does it expire?

Patent 9,517,219 protects ACZONE and is included in one NDA.

This patent has twenty-one patent family members in fifteen countries.

Summary for Patent: 9,517,219
Title:Topical dapsone and dapsone/adapalene compositions and methods for use thereof
Abstract: Dapsone and dapsone/adapalene compositions can be useful for treating a variety of dermatological conditions. The compositions of this disclosure include dapsone and/or adapalene in a polymeric viscosity builder. Subject compositions can be adjusted to optimize the dermal delivery profile of dapsone to effectively treat dermatological conditions and improve the efficiency of pharmaceutical products applied to the skin. Use of the polymeric viscosity builder provides compositions with increased concentrations of diethylene glycol monoethyl ether relative to compositions without the polymeric viscosity builder.
Inventor(s): Warner; Kevin S. (Anaheim, CA), Parashar; Ajay P. (Fairfax, VA), Swaminathan; Vijaya (San Francisco, CA), Bhatt; Varsha (San Francisco, CA)
Assignee: Allergan, Inc. (Irvine, CA)
Application Number:14/885,805
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,517,219
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 9,517,219

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Almirall ACZONE dapsone GEL;TOPICAL 207154-001 Feb 24, 2016 AB RX Yes Yes   Start Trial   Start Trial TOPICAL TREATMENT OF ACNE VULGARIS   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,517,219

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2013348247   Start Trial
Australia 2018214139   Start Trial
Brazil 112015011673   Start Trial
Canada 2890224   Start Trial
China 105246457   Start Trial
Denmark 2922528   Start Trial
European Patent Office 2922528   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Mallinckrodt
Express Scripts
Baxter
Boehringer Ingelheim
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.